The Honest Reason: Choosing Phentermine-Topiramate Because She Can Actually Afford It
A woman with treated hypertension and an uncovered weight-loss drug benefit is offered phentermine-topiramate over a GLP-1 agonist — a choice driven openly by affordability, with real cardiovascular monitoring built in given phentermine's sympathomimetic effects.
Priscilla N., a 45-year-old dental hygienist, brought a printed insurance denial letter to her appointment, folded into quarters, before she'd said much else about why she'd come in. Her employer-sponsored plan, like most she'd checked, explicitly excludes weight-loss medications from coverage regardless of which drug class or brand is prescribed, and a month of any GLP-1 agonist at list price would run close to what she pays in rent. Her BMI is 32, her blood pressure has been controlled on lisinopril and amlodipine for the past four years, and she was direct about what she actually needed from this visit: something that works and something she can keep paying for past the first month.
That combination of requirements points the conversation somewhere specific. Phentermine-topiramate, available generically, costs a small fraction of a branded GLP-1 agonist at cash price and produces real, clinically meaningful weight loss in its own right, though generally less than the newer incretin-based drugs achieve. The honest complication isn't efficacy; it's that phentermine, a sympathomimetic amine, raises heart rate and blood pressure in a dose-dependent way — a real consideration in a patient whose blood pressure, while currently well controlled, has needed two separate medications to get there rather than one. Her resting heart rate today is 76, which leaves genuine headroom before any rise becomes clinically interesting, and which is chiefly valuable as the number every later reading will be measured against — worth having on the chart before the first dose rather than reconstructed from memory after a complaint.
Priscilla's own priority, stated plainly, was sustainability over theoretical maximum effect, and today's visit is about whether a drug she can actually keep taking can also be made safe enough, with the right monitoring, to recommend confidently given her cardiovascular history.
In clinic, a folded denial letter and an honest constraint
I'd offer her phentermine-topiramate rather than a GLP-1 agonist, and cost is the honest, primary reason. Her insurance doesn't cover weight-loss indications for either drug class, and phentermine-topiparate at generic pricing runs a small fraction of the out-of-pocket cost of a branded GLP-1 agonist — a difference that determines whether she can actually sustain treatment, not just whether it's theoretically the more effective option on paper.
I don't dispute the cost gap, and I think it's a legitimate, load-bearing part of this decision rather than a lesser concern to work around. But phentermine, the sympathomimetic component, is not free of cardiovascular signal — it raises heart rate and blood pressure in a dose-dependent way, and her own blood pressure, while currently controlled, has needed two medications to get there. I'd want that named to her explicitly, not folded into a generic 'common side effects' disclosure.
None of that makes phentermine-topiramate the wrong choice for her specifically — her cardiovascular risk is currently well controlled, not a contraindication — but a drug she can afford and actually take safely requires her blood pressure and heart rate to be tracked more closely than a routine follow-up schedule would otherwise call for.
Agreed, and I'd build that monitoring in explicitly rather than leave it implicit: home blood pressure checks twice weekly for the first two months, with a lower threshold than usual for an earlier in-person recheck if either her pressure or resting heart rate trends up meaningfully during titration.
Agreed: start phentermine-topiramate at the lowest titration dose, with home blood pressure and heart rate monitoring twice weekly for the first two months and a lower threshold for an earlier in-person recheck if either trends upward.
No real disagreement remained; both physicians were explicit with Priscilla that this was a genuinely reasonable choice given her actual constraints, not a lesser option chosen only because the better one was unaffordable — a distinction both felt was worth stating to her directly rather than leaving implied.